Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immunotherapy: Combine and conquer

× No keyword cloud information.

3 in total

1. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade.

Authors: Martina Schmittnaegel; Nicolò Rigamonti; Ece Kadioglu; Antonino Cassará; Céline Wyser Rmili; Anna Kiialainen; Yvonne Kienast; Hans-Joachim Mueller; Chia-Huey Ooi; Damya Laoui; Michele De Palma
Journal: Sci Transl Med Date: 2017-04-12 Impact factor: 17.956

2. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.

Authors: Elizabeth Allen; Arnaud Jabouille; Lee B Rivera; Inge Lodewijckx; Rindert Missiaen; Veronica Steri; Kevin Feyen; Jaime Tawney; Douglas Hanahan; Iacovos P Michael; Gabriele Bergers
Journal: Sci Transl Med Date: 2017-04-12 Impact factor: 17.956

3. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming.

Authors: Lin Tian; Amit Goldstein; Hai Wang; Hin Ching Lo; Ik Sun Kim; Thomas Welte; Kuanwei Sheng; Lacey E Dobrolecki; Xiaomei Zhang; Nagireddy Putluri; Thuy L Phung; Sendurai A Mani; Fabio Stossi; Arun Sreekumar; Michael A Mancini; William K Decker; Chenghang Zong; Michael T Lewis; Xiang H-F Zhang
Journal: Nature Date: 2017-04-03 Impact factor: 49.962

3 in total

1 in total

1. Activation of the chemokine receptor 3 pathway leads to a better response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma.

Authors: Wenqin Feng; Anqi Lin; Le Sun; Ting Wei; Haoxuan Ying; Jian Zhang; Peng Luo; Weiliang Zhu
Journal: Cancer Cell Int Date: 2022-05-13 Impact factor: 6.429

1 in total

Immunotherapy: Combine and conquer - antiangiogenic immunotherapy.

1. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade.

2. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.

3. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming.

1. Activation of the chemokine receptor 3 pathway leads to a better response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma.